Shionogi Increases ViiV Healthcare Stake to 21.7% in $2.13 Billion Deal as Pfizer Exits HIV Joint Venture
核心洞察
Shionogi (搜索) will invest $2.13 billion to increase its economic interest in ViiV Healthcare to 21.7% as Pfizer exits its 11.7% stake in the HIV (搜索) specialist company.
The transaction simplifies ViiV Healthcare's shareholder structure while maintaining GSK's 78.3% majority ownership of the global HIV (搜索) medicines developer.
ViiV Healthcare currently markets 15 prescription HIV (搜索) medicines and is developing ultra long-acting therapies, competing in a market forecast to grow from $26.5 billion in 2023 to $32.1 billion by 2033.
Japanese pharmaceutical company Shionogi (搜索) & Co will significantly expand its stake in ViiV Healthcare through a $2.13 billion investment, as Pfizer exits the HIV (搜索) specialist joint venture after 17 years of partnership. The transaction will increase Shionogi's economic interest in ViiV Healthcare from its current level to 21.7%, while GSK maintains its 78.3% majority ownership.
Under the agreement, ViiV Healthcare will issue new shares to Shionogi (搜索) for $2.125 billion and cancel Pfizer's 11.7% holding in the company. Pfizer will receive $1.875 billion from the transaction, while GSK will receive a special dividend of $250 million. The deal is expected to complete during the first quarter of 2026, subject to regulatory clearances in relevant markets.
Strategic Partnership Strengthened
The transaction marks the end of Pfizer's involvement with ViiV Healthcare, which was originally established as a joint venture between GSK and Pfizer in 2009. Shionogi (搜索) joined as a shareholder in 2012 and will continue to hold one director position on the ViiV Healthcare board, represented by Dr. John Keller.
"This agreement simplifies ViiV's shareholder structure and we look forward to continuing our highly successful collaboration with Shionogi (搜索) to advance ViiV's pipeline and portfolio of long-acting injectable HIV (搜索) treatment and prevention medicines," said David Redfern, chair of ViiV Healthcare.
Dr. John Keller, Director of the Board and Senior Vice President of R&D Supervisory Unit at Shionogi (搜索), emphasized the company's commitment to HIV (搜索) research: "Shionogi is dedicated to addressing major infectious diseases, with HIV being one of our most important focus areas, as reflected by our role in the discovery of the innovative integrase (搜索) inhibitors dolutegravir and cabotegravir."
Current Portfolio and Pipeline Focus
ViiV Healthcare currently operates with a portfolio of 15 prescription HIV (搜索) medicines and has four candidates in clinical trials. The company is particularly focused on developing ultra long-acting therapies for treatment and prevention, including long-acting injectables that could be self-administered.
This strategic direction aligns with recent developments in the HIV (搜索) treatment landscape, particularly following Gilead's Yeztugo (搜索) (lenacapavir), which became the first and only biannual pre-exposure prophylaxis (PrEP) to win approval in the US and Europe in 2025. In Phase III trials, Gilead's twice-yearly drug demonstrated near perfect efficacy, preventing nearly 100% of HIV cases in patients who received the study drug.
Shionogi (搜索)'s ongoing HIV (搜索) research continues to contribute to ViiV's pipeline through licensing agreements, including the third-generation integrase (搜索) inhibitor S-395598 (搜索)/VH 4524184.
Market Dynamics and Growth Outlook
The HIV (搜索) market across the seven major markets (US, France, Germany, Italy, Spain, the UK, and Japan) is forecast to grow at a compound annual growth rate of 1.9% from $26.5 billion in 2023 to $32.1 billion in 2033, according to GlobalData forecasts.
The HIV (搜索) treatment space remains heavily dominated by Gilead Sciences, particularly following the announcement of data from Phase III trials of its twice-yearly PrEP medication. However, the market faces challenges from global funding cuts that have impacted HIV treatment efforts, particularly affecting services in low-income countries supported by international aid programs.
Financial Impact
Shares in Tokyo-listed Shionogi rose 2.8% to ¥2,925 ($18.53) at market open on January 20, compared to the previous day's market close of ¥2,840.5. Upon completion of the transaction, GSK will extinguish the Pfizer put option liability through retained earnings, with the liability remeasured immediately prior to completion using the same methodology as at December 31, 2025.